Cat. No.: HY-17367A

Atazanavir sulfate

(Synonyms: BMS-232632 sulfate)

13 Cited Publications

Customer Review

Based on 13 publication(s) in Google Scholar

Atazanavir (BMS-232632) sulfate is a highly selective and orally active HIV-1 protease inhibitor with blood-brain barrier permeability. Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CL^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir sulfate inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death.

For research use only. We do not sell to patients.

Purity: 99.68%
CAS No.: 229975-97-7
Formula: C₃₈H₅₄N₆O₁₁S
Molecular Weight:802.93

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Atazanavir sulfate Chemical Structure

CAS No.: 229975-97-7

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
- Clinical Trial
Chemical Information
Publications (13)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

CYP3

HIV-1

All HIV Isoforms :

All Cytochrome P450 Isoforms :

All Toll-like Receptor (TLR) Isoforms :

In Vitro

Atazanavir (1-10 μM, 72 h) attenuates hypoxia induced rat cardiac fibroblasts (rCFs) s proliferation by modulating the HMGB1/TLR 9 pathway^[4].
Atazanavir (1-10 μM, 72 h) inhibits collagen I, collagen III, HMGB1, p-IκBα and p-NF-κB expression levels in rat cardiac fibroblasts^[4].
Atazanavir (1-10 μM, 48 h) inhibits the growth of A, U251, T98G, LN229 cells and induces ESR (endoplasmic reticulum stress response) in U251, T98G, and LN229 cells^[6].
Atazanavir (6.0 μM) elicites Ca2+ transients and blebbing of the plasma membranes of C2C12 skeletal muscle myotubes^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[4]

Cell Line:

Rat cardiac fibroblasts (rCFs)
Concentration:

0, 1, 3, 10 μM
Incubation Time:

72 h
Result:

Inhibited rCFs proliferation in a concentration-dependent manner.

Western Blot Analysis^[4]

Cell Line:

Rat cardiac fibroblasts (rCFs)
Concentration:

0, 1, 3, 10 μM
Incubation Time:

72 h
Result:

Reduced collagen I and collagen III levels in a concentration-dependent manner.
Inhibited HMGB1, p-IκBα and p-NF-κB expression.

Cell Viability Assay^[6]

Cell Line:

A, U251, T98G, LN229 glioblastoma cell
Concentration:

0, 12, 25, 50, 75, 100 μM
Incubation Time:

48 h
Result:

Reduced cell growth and survival.

Western Blot Analysis^[6]

Cell Line:

U251, T98G, and LN229 glioblastoma cell lines
Concentration:

0, 12, 25, 50, 75, 100 μM
Incubation Time:

48 h
Result:

Increased GRP78 and CHOP protein levels dose-dependently and activated caspase-4 in all cell lines.

Parmacokinetics

Species	Dose	Route	T_1/2	AUC	Clearance (CL)	V_d	T_max
Rat	7 mg/kg	i.p.	1.22 h	3.38 μg·h/mL	/	/	/
Rat	7 mg/kg	i.v.	1.13 h	4.09 μg·h/mL	1.77 L/h/kg	2.23 L/kg	/
Rat	7 mg/kg	p.o.	1.04 h	1.70 μg·h/mL	0.54 μg/mL	/	2.25 h

In Vivo

Atazanavir (30 mg/kg, i.g., daily, 4 weeks) reduces collagen deposition and inhibits cardiac remodeling in myocardial infarction (MI) model rats^[4].
Atazanavir sulfate has poor blood-brain barrier (BBB) ??permeability, but it can be verified in vitro using human BBB models^[8]^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

The myocardial infarction (MI) model was established in adult male Sprague-Dawley rats through surgical procedures^[4].
Dosage:

30 mg/kg
Administration:

i.g., daily, 4 weeks
Result:

Significantly improved systolic pressure (LVSP), +dp/dtmax and −dp/dtmax after MI.
Decreased the non-infarcted LV and hypertrophy of the myocytes.
Significantly attenuated an increase in morphometrical collagen volume fraction in the border left ventricle.
Lowered the heart index (heart-weight to body-weight ratio).
Decreased expressions of α-SMA, HMGB1, TLR 9, p-NF-κB, collagen I and collagen III, and the content of Hyp.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 229975-97-7
Appearance Solid
Molecular Weight 802.93
Formula C₃₈H₅₄N₆O₁₁S
Color White to light yellow
SMILES

O=C(OC)N[C@@H](C(C)(C)C)C(NN(CC1=CC=C(C2=NC=CC=C2)C=C1)C[C@H](O)[C@H](CC3=CC=CC=C3)NC([C@H](C(C)(C)C)NC(OC)=O)=O)=O.O=S(O)(O)=O
Synonyms

BMS-232632 sulfate
Structure Classification
- Alkaloids
- Pyridine Alkaloids
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (13)

All

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Signal Transduct Target Ther

Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. [Abstract]

2021 May 29;6(1):212. PMID: 34052830
Nat Commun

Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. [Abstract]

2020 Apr 14;11(1):1792. PMID: 32286289
Nat Commun

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. [Abstract]

2020 Sep 4;11(1):4417. PMID: 32887884
PLoS Biol

A proteomic atlas of senescence-associated secretomes for aging biomarker development. [Abstract]

2020 Jan 16;18(1):e3000599. PMID: 31945054
Aging Cell

Antiretroviral protease inhibitors induce features of cellular senescence that are reversible upon drug removal. [Abstract]

2023 Jan;22(1):e13750. PMID: 36539941
J Photochem Photobiol A Chem

2025 Nov 15;473:116930.
Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744
Antimicrob Agents Chemother

Discovery of M Protease Inhibitors Encoded by SARS-CoV-2. [Abstract]

2020 Aug 20;64(9):e00872-20. PMID: 32669265
Curr Protoc

Quantitative Proteomic Analysis of the Senescence-Associated Secretory Phenotype by Data-Independent Acquisition. [Abstract]

2021 Feb;1(2):e32. PMID: 33524224
Research Square Print

2022 May.
bioRxiv

2020 Apr.
University of Oxford

2019 Jul.

Solvent & Solubility

In Vitro:

DMSO : 166 mg/mL (206.74 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2454 mL

6.2272 mL

12.4544 mL

5 mM

0.2491 mL

1.2454 mL

2.4909 mL

10 mM

0.1245 mL

0.6227 mL

1.2454 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline